Prostate Cancer Theranostics – Current Evidence and Future Considerations: a Brief Overview
Despite initial response to androgen inhibition, metastatic prostate cancer is invariably an incurable disease. New agents with different mechanisms of action are needed that are capable of producing clinical benefit and prolonging survival. New breakthroughs specific to prostate cancer are being...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sestre Milosrdnice University hospital, Institute of Clinical Medical Research
2024-01-01
|
| Series: | Acta Clinica Croatica |
| Subjects: | |
| Online Access: | https://hrcak.srce.hr/file/467298 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850263199804293120 |
|---|---|
| author | Antonela Njavro Jure Murgić Blanka Jakšić Marin Prpić Angela Prgomet Sečan Dražen Huić Dinko Franceschi Ana Fröbe |
| author_facet | Antonela Njavro Jure Murgić Blanka Jakšić Marin Prpić Angela Prgomet Sečan Dražen Huić Dinko Franceschi Ana Fröbe |
| author_sort | Antonela Njavro |
| collection | DOAJ |
| description | Despite initial response to androgen inhibition, metastatic prostate cancer is invariably
an incurable disease. New agents with different mechanisms of action are needed that are capable of
producing clinical benefit and prolonging survival. New breakthroughs specific to prostate cancer are being
made by combining novel diagnostic molecular imaging modalities with cytotoxic radionuclide payloads
to cancer cells and the surrounding tumor microenvironment. This concept yielded unprecedented
clinical responses in a very challenging population of patients. Targeted radionuclide therapy, mainly
targeting prostate-specific antigen (PSMA), is now considered the new standard of care for patients
with advanced disease who have progressed to the use of new androgen suppressors and chemotherapy.
Targeted radionuclide therapy, mainly focused on prostate-specific antigen, is now considered the new
treatment standard for patients with more aggressive disease who have been treated with new androgen
suppressors and chemotherapy. The application of the theranostic paradigm has enabled personalized
management of prostate cancer patients, with significant potential for future development in the form
of a combination therapy with other agents. This freeform review article summarizes the key clinical
research in the field of radionuclide targeted therapy for prostate cancer and provides an overview of
current practice in this rapidly evolving entity. |
| format | Article |
| id | doaj-art-ffbc10a9b86e4286afb7c8b1d8a1438e |
| institution | OA Journals |
| issn | 0353-9466 1333-9451 |
| language | English |
| publishDate | 2024-01-01 |
| publisher | Sestre Milosrdnice University hospital, Institute of Clinical Medical Research |
| record_format | Article |
| series | Acta Clinica Croatica |
| spelling | doaj-art-ffbc10a9b86e4286afb7c8b1d8a1438e2025-08-20T01:55:02ZengSestre Milosrdnice University hospital, Institute of Clinical Medical ResearchActa Clinica Croatica0353-94661333-94512024-01-0163.Supplement 2828710.20471/acc.2024.63.s2.13Prostate Cancer Theranostics – Current Evidence and Future Considerations: a Brief OverviewAntonela Njavro0Jure Murgić1Blanka Jakšić2Marin Prpić3Angela Prgomet Sečan4Dražen Huić5Dinko Franceschi6Ana Fröbe7Department of Oncology and Nuclear Medicine, University Hospital Center Sestre Milosrdnice, Zagreb, CroatiaDepartment of Oncology and Nuclear Medicine, University Hospital Center Sestre Milosrdnice, Zagreb, CroatiaDepartment of Oncology and Nuclear Medicine, University Hospital Center Sestre Milosrdnice, Zagreb, CroatiaDepartment of Oncology and Nuclear Medicine, University Hospital Center Sestre Milosrdnice, Zagreb, Croatia; School of Dental Medicine, University of Zagreb, Zagreb, CroatiaDepartment of Oncology and Nuclear Medicine, University Hospital Center Sestre Milosrdnice, Zagreb, CroatiaClinical Department of Nuclear Medicine and Radiation Protection, Zagreb University Hospital Centre, Zagreb, Croatia; School of Medicine, University of Zagreb, Zagreb, CroatiaDepartment of Radiology, Renaissance School of Medicine, Stony Brook University, Stony Brook, New York, USADepartment of Oncology and Nuclear Medicine, University Hospital Center Sestre Milosrdnice, Zagreb, Croatia; School of Dental Medicine, University of Zagreb, Zagreb, CroatiaDespite initial response to androgen inhibition, metastatic prostate cancer is invariably an incurable disease. New agents with different mechanisms of action are needed that are capable of producing clinical benefit and prolonging survival. New breakthroughs specific to prostate cancer are being made by combining novel diagnostic molecular imaging modalities with cytotoxic radionuclide payloads to cancer cells and the surrounding tumor microenvironment. This concept yielded unprecedented clinical responses in a very challenging population of patients. Targeted radionuclide therapy, mainly targeting prostate-specific antigen (PSMA), is now considered the new standard of care for patients with advanced disease who have progressed to the use of new androgen suppressors and chemotherapy. Targeted radionuclide therapy, mainly focused on prostate-specific antigen, is now considered the new treatment standard for patients with more aggressive disease who have been treated with new androgen suppressors and chemotherapy. The application of the theranostic paradigm has enabled personalized management of prostate cancer patients, with significant potential for future development in the form of a combination therapy with other agents. This freeform review article summarizes the key clinical research in the field of radionuclide targeted therapy for prostate cancer and provides an overview of current practice in this rapidly evolving entity.https://hrcak.srce.hr/file/467298Prostate-specific membrane antigen (PSMA)PeptideRadionuclideRadiotherapyAlpha particleProstate cancer |
| spellingShingle | Antonela Njavro Jure Murgić Blanka Jakšić Marin Prpić Angela Prgomet Sečan Dražen Huić Dinko Franceschi Ana Fröbe Prostate Cancer Theranostics – Current Evidence and Future Considerations: a Brief Overview Acta Clinica Croatica Prostate-specific membrane antigen (PSMA) Peptide Radionuclide Radiotherapy Alpha particle Prostate cancer |
| title | Prostate Cancer Theranostics – Current Evidence and Future Considerations: a Brief Overview |
| title_full | Prostate Cancer Theranostics – Current Evidence and Future Considerations: a Brief Overview |
| title_fullStr | Prostate Cancer Theranostics – Current Evidence and Future Considerations: a Brief Overview |
| title_full_unstemmed | Prostate Cancer Theranostics – Current Evidence and Future Considerations: a Brief Overview |
| title_short | Prostate Cancer Theranostics – Current Evidence and Future Considerations: a Brief Overview |
| title_sort | prostate cancer theranostics current evidence and future considerations a brief overview |
| topic | Prostate-specific membrane antigen (PSMA) Peptide Radionuclide Radiotherapy Alpha particle Prostate cancer |
| url | https://hrcak.srce.hr/file/467298 |
| work_keys_str_mv | AT antonelanjavro prostatecancertheranosticscurrentevidenceandfutureconsiderationsabriefoverview AT juremurgic prostatecancertheranosticscurrentevidenceandfutureconsiderationsabriefoverview AT blankajaksic prostatecancertheranosticscurrentevidenceandfutureconsiderationsabriefoverview AT marinprpic prostatecancertheranosticscurrentevidenceandfutureconsiderationsabriefoverview AT angelaprgometsecan prostatecancertheranosticscurrentevidenceandfutureconsiderationsabriefoverview AT drazenhuic prostatecancertheranosticscurrentevidenceandfutureconsiderationsabriefoverview AT dinkofranceschi prostatecancertheranosticscurrentevidenceandfutureconsiderationsabriefoverview AT anafrobe prostatecancertheranosticscurrentevidenceandfutureconsiderationsabriefoverview |